%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
Katrin Lorenz, Joanna Wasielica-Poslednik, Katharina Bell, Giulia Renieri, Alexander Keicher, Christian Ruckes, Norbert Pfeiffer, Hagen Thieme
Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma
www.plosone.org
www.plosone.org
endstream
endobj
3 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 12 0 R/Annots 13 0 R/Contents 14 0 R/TrimBox[0 0 612 792]>>
endobj
13 0 obj
[15 0 R 16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R 22 0 R 23 0 R 24 0 R 25 0 R 26 0 R 27 0 R]
endobj
15 0 obj
<>/Border[0 0 0]/Dest(Rpone.0171636.ref001)>>
endobj
16 0 obj
<>/Border[0 0 0]/Dest(Rpone.0171636.ref002)>>
endobj
17 0 obj
<>/Border[0 0 0]/Dest(Rpone.0171636.ref004)>>
endobj
18 0 obj
<>/Border[0 0 0]/Dest(Rpone.0171636.ref005)>>
endobj
19 0 obj
<>/Border[0 0 0]/Dest(Rpone.0171636.ref007)>>
endobj
20 0 obj
<>/Border[0 0 0]/Dest(Rpone.0171636.ref008)>>
endobj
21 0 obj
<>/Border[0 0 0]/Dest(Rpone.0171636.ref009)>>
endobj
22 0 obj
<>/Border[0 0 0]/Dest(Rpone.0171636.ref010)>>
endobj
23 0 obj
<>/Border[0 0 0]/Dest(Rpone.0171636.ref011)>>
endobj
24 0 obj
<>/Border[0 0 0]/Dest(Rpone.0171636.ref012)>>
endobj
25 0 obj
<>/Border[0 0 0]/Dest(Rpone.0171636.ref013)>>
endobj
26 0 obj
<>/Border[0 0 0]/Dest(Rpone.0171636.ref015)>>
endobj
27 0 obj
<>/Border[0 0 0]/Dest(Rpone.0171636.ref012)>>
endobj
14 0 obj
[28 0 R 29 0 R 30 0 R 31 0 R 32 0 R 33 0 R 34 0 R 35 0 R 36 0 R 37 0 R 38 0 R 39 0 R 40 0 R 41 0 R]
endobj
28 0 obj
<>stream
q
0.45 0.36 0.35 0.01 k
0 w
575.9997 588.1144 m
199.9998 588.1144 l
199.9998 588.6145 l
575.9997 588.6145 l
f*
0.83 0.64 0.02 0 k
564.2646 497.9339 m
569.0268 497.9339 l
h
f*
480.4724 445.9465 m
485.2346 445.9465 l
h
f*
490.3937 445.9465 m
495.1559 445.9465 l
h
f*
380.3528 432.9071 m
385.115 432.9071 l
h
f*
390.3307 432.9071 m
395.0929 432.9071 l
h
f*
395.5465 380.9197 m
400.3087 380.9197 l
h
f*
476.1071 380.9197 m
480.8693 380.9197 l
h
f*
522.4252 315.9496 m
531.9496 315.9496 l
h
f*
526.4504 302.9102 m
535.9181 302.9102 l
h
f*
503.6598 276.9449 m
513.1843 276.9449 l
h
f*
298.5449 263.9055 m
308.0693 263.9055 l
h
f*
313.2283 263.9055 m
322.7528 263.9055 l
h
f*
375.3638 198.9354 m
384.8315 198.9354 l
h
f*
0 g
1 j
1 J
9.5 0 0 9.5 200.0125 707.7543 cm
BT
/F0 1 Tf
1 TL
-0.0042 Tc
0 0 Td
(the)Tj
1.5933 0 Td
(classification)Tj
5.8185 0 Td
(of)Tj
1.0443 0 Td
(the)Tj
1.5934 0 Td
(filtering)Tj
3.3956 0 Td
(bleb,)Tj
2.3572 0 Td
(corneal)Tj
3.4553 0 Td
(staining,)Tj
3.8969 0 Td
(and)Tj
1.8678 0 Td
(numbers)Tj
4.07 0 Td
(of)Tj
1.0503 0 Td
(treatments)Tj
4.8994 0 Td
(with)Tj
1.9813 0 Td
(5-FU,)Tj
-37.0233 -1.474 Td
(needlings)Tj
4.4399 0 Td
(and)Tj
1.8619 0 Td
(suture)Tj
2.9719 0 Td
(lyses.)Tj
2.7511 0 Td
(More)Tj
2.4766 0 Td
(patients)Tj
3.682 0 Td
(reported)Tj
3.8969 0 Td
(AEs)Tj
2.0469 0 Td
(in)Tj
0.9846 0 Td
(the)Tj
1.5934 0 Td
(acetazolamide/dexam)Tj
9.6199 0 Td
(etha-)Tj
-36.3251 -1.474 Td
(sone)Tj
2.3631 0 Td
(group)Tj
2.7452 0 Td
(than)Tj
2.1424 0 Td
(in)Tj
0.9846 0 Td
(the)Tj
1.5934 0 Td
(dorzolamide/timolol)Tj
8.7247 0 Td
(group.)Tj
ET
Q
q
1 j
1 J
0 w
11.4998 0 0 11.4998 200.0125 632.6362 cm
BT
/F2 1 Tf
1 TL
-0.0035 Tc
0 0 Td
(Discussion)Tj
ET
Q
q
1 j
1 J
0 w
9.5 0 0 9.5 200.0125 615.6283 cm
BT
/F0 1 Tf
1 TL
-0.0042 Tc
0 0 Td
(Preoperative,)Tj
6.0989 0 Td
(preservative)Tj
5.3888 0 Td
(-free,)Tj
2.5303 0 Td
(fixed-dose)Tj
4.7801 0 Td
(dorzolamide/timolol)Tj
8.7247 0 Td
(seems)Tj
3.139 0 Td
(to)Tj
1.0443 0 Td
(be)Tj
1.3189 0 Td
(equally)Tj
3.3418 0 Td
(effec-)Tj
-36.3668 -1.474 Td
(tive)Tj
1.7544 0 Td
(as)Tj
1.2652 0 Td
(preoperative)Tj
5.711 0 Td
(acetazolamide)Tj
6.5943 0 Td
(and)Tj
1.8619 0 Td
(dexamethason)Tj
6.4928 0 Td
(e)Tj
0.7698 0 Td
(and)Tj
1.8679 0 Td
(has)Tj
1.8082 0 Td
(a)Tj
0.7698 0 Td
(favourable)Tj
4.8338 0 Td
(safety)Tj
2.8645 0 Td
(profile.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 516.0188 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Introduction)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 499.011 cm
BT
/F6 1 Tf
1 TL
-0.004 Tc
0 0 Td
(The)Tj
1.7801 0 Td
(most)Tj
2.2053 0 Td
(common)Tj
3.8495 0 Td
(cause)Tj
2.3867 0 Td
(of)Tj
1.0148 0 Td
(post-trabeculectomy)Tj
8.4132 0 Td
(filtration)Tj
3.7474 0 Td
(failure)Tj
2.7779 0 Td
(is)Tj
0.8447 0 Td
(postoperative)Tj
5.6012 0 Td
(scarring)Tj
3.464 0 Td
([)Tj
0.83 0.64 0.02 0 k
(1)Tj
0 g
(].)Tj
-36.0848 -1.3039 Td
(Long-term)Tj
4.541 0 Td
(preoperative)Tj
5.2271 0 Td
(treatment)Tj
4.1385 0 Td
(with)Tj
1.9956 0 Td
(topical)Tj
2.914 0 Td
(antiglaucoma)Tj
5.6239 0 Td
(agents)Tj
2.7496 0 Td
(containing)Tj
4.5297 0 Td
(preservatives,)Tj
-31.7194 -1.2982 Td
(usually)Tj
3.016 0 Td
(benzalkonium)Tj
5.9584 0 Td
(chloride,)Tj
3.7417 0 Td
(leads)Tj
2.211 0 Td
(to)Tj
1.0261 0 Td
(histologic)Tj
4.0876 0 Td
(changes)Tj
3.4072 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(conjunctiva,)Tj
5.1364 0 Td
(with)Tj
1.9955 0 Td
(increased)Tj
-33.063 -1.2983 Td
(numbers)Tj
3.7757 0 Td
(and)Tj
1.7348 0 Td
(activity)Tj
3.1124 0 Td
(of)Tj
1.0148 0 Td
(lymphocytes,)Tj
5.4822 0 Td
(monocytes,)Tj
4.7905 0 Td
(fibroblasts,)Tj
4.5921 0 Td
(and)Tj
1.7291 0 Td
(conjunctival)Tj
5.1533 0 Td
(goblet)Tj
2.6703 0 Td
(cells.)Tj
-34.0552 -1.2983 Td
(These)Tj
2.5681 0 Td
(changes)Tj
3.4016 0 Td
(may)Tj
1.9275 0 Td
(favour)Tj
2.8006 0 Td
(the)Tj
1.474 0 Td
(development)Tj
5.4085 0 Td
(of)Tj
1.0148 0 Td
(filtration)Tj
3.7474 0 Td
(bleb)Tj
1.8992 0 Td
(scarring)Tj
3.4639 0 Td
([)Tj
0.83 0.64 0.02 0 k
(2)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(4)Tj
0 g
(])Tj
2.3698 0 Td
(and)Tj
1.7291 0 Td
(increase)Tj
3.4752 0 Td
(the)Tj
-35.2797 -1.3039 Td
(rate)Tj
1.7461 0 Td
(of)Tj
1.0148 0 Td
(post-trabeculectomy)Tj
8.4132 0 Td
(filtration)Tj
3.7473 0 Td
(failure)Tj
2.778 0 Td
([)Tj
0.83 0.64 0.02 0 k
(5)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(7)Tj
0 g
(].)Tj
2.5908 0 Td
(Given)Tj
2.6306 0 Td
(these)Tj
2.2506 0 Td
(considerations,)Tj
6.2929 0 Td
(Broadway)Tj
4.2123 0 Td
(et)Tj
0.9411 0 Td
(al)Tj
-36.6177 -1.2982 Td
(proposed)Tj
3.9514 0 Td
(discontinuing)Tj
5.777 0 Td
(antiglaucoma)Tj
5.6239 0 Td
(drugs)Tj
2.4718 0 Td
(and)Tj
1.7348 0 Td
(treating)Tj
3.3222 0 Td
(patients)Tj
3.3675 0 Td
(preoperatively)Tj
5.93 0 Td
(with)Tj
2.0013 0 Td
(topical)Tj
-34.1799 -1.2983 Td
(steroids.)Tj
3.5602 0 Td
(Many)Tj
2.5512 0 Td
(surgeons)Tj
3.7871 0 Td
(therefore)Tj
3.8494 0 Td
(prepare)Tj
3.2825 0 Td
(their)Tj
2.1033 0 Td
(patients)Tj
3.3732 0 Td
(for)Tj
1.3833 0 Td
(planned)Tj
3.4639 0 Td
(trabeculectomy)Tj
6.3836 0 Td
(by)Tj
1.1792 0 Td
(stop-)Tj
-34.9169 -1.3039 Td
(ping)Tj
2.0182 0 Td
(topical)Tj
2.914 0 Td
(antiglaucoma)Tj
5.6239 0 Td
(drugs,)Tj
2.6986 0 Td
(controlling)Tj
4.6488 0 Td
(intraocular)Tj
4.6487 0 Td
(pressure)Tj
3.5773 0 Td
(\(IOP\))Tj
2.5455 0 Td
(with)Tj
1.9956 0 Td
(oral)Tj
1.7802 0 Td
(acetazol-)Tj
-32.4508 -1.2983 Td
(amide,)Tj
2.9139 0 Td
(and)Tj
1.7348 0 Td
(treating)Tj
3.3222 0 Td
(the)Tj
1.474 0 Td
(eye)Tj
1.5194 0 Td
(with)Tj
1.9956 0 Td
(topical)Tj
2.914 0 Td
(steroids)Tj
3.3392 0 Td
([)Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
(].)Tj
1.5987 0 Td
(Breusegem)Tj
4.6148 0 Td
(et)Tj
0.9411 0 Td
(al)Tj
0.9014 0 Td
([)Tj
0.83 0.64 0.02 0 k
(9)Tj
0 g
(])Tj
1.3776 0 Td
(showed)Tj
3.2485 0 Td
(the)Tj
1.4683 0 Td
(usefulness)Tj
-33.3635 -1.2983 Td
(of)Tj
1.0147 0 Td
(this)Tj
1.6725 0 Td
(approach)Tj
3.9514 0 Td
(in)Tj
1.0375 0 Td
(a)Tj
0.652 0 Td
(randomized,)Tj
5.2837 0 Td
(controlled,)Tj
4.5468 0 Td
(three-arm)Tj
4.2406 0 Td
(study.)Tj
2.6135 0 Td
(This)Tj
1.9899 0 Td
(preoperative)Tj
5.2271 0 Td
(treatment)Tj
4.1329 0 Td
(led)Tj
-36.3626 -1.3039 Td
(to)Tj
1.0261 0 Td
(fewer)Tj
2.4094 0 Td
(filtering)Tj
3.3959 0 Td
(bleb)Tj
1.8992 0 Td
(revisions)Tj
3.7814 0 Td
(postoperatively.)Tj
6.531 0 Td
(In)Tj
1.1055 0 Td
(addition,)Tj
3.8267 0 Td
(fewer)Tj
2.4095 0 Td
(IOP-lowering)Tj
5.7259 0 Td
(medications)Tj
-32.1106 -1.2982 Td
(were)Tj
2.1203 0 Td
(necessary.)Tj
4.2462 0 Td
(Preoperative)Tj
5.2724 0 Td
(treatment)Tj
4.1329 0 Td
(still)Tj
1.6384 0 Td
(differs)Tj
2.7496 0 Td
(significantly)Tj
5.091 0 Td
(between)Tj
3.5263 0 Td
(centres.)Tj
3.2938 0 Td
(The)Tj
1.7858 0 Td
(results)Tj
-33.8567 -1.2983 Td
(published)Tj
4.1215 0 Td
(to)Tj
1.0261 0 Td
(date)Tj
1.9049 0 Td
(have)Tj
2.0579 0 Td
(often)Tj
2.2848 0 Td
(been)Tj
2.1203 0 Td
(based)Tj
2.4718 0 Td
(on)Tj
1.2755 0 Td
(retrospective,)Tj
5.5843 0 Td
(nonrandomized,)Tj
6.8881 0 Td
(nonmasked)Tj
4.8869 0 Td
(investi-)Tj
-34.6221 -1.2983 Td
(gations)Tj
3.101 0 Td
(and)Tj
1.7292 0 Td
(have)Tj
2.0579 0 Td
(not)Tj
1.576 0 Td
(studied)Tj
3.1522 0 Td
(the)Tj
1.4683 0 Td
(latest)Tj
2.2847 0 Td
(generation)Tj
4.5071 0 Td
(of)Tj
1.0148 0 Td
(topical)Tj
2.914 0 Td
(antiglaucoma)Tj
5.6239 0 Td
(drugs)Tj
2.4718 0 Td
([)Tj
0.83 0.64 0.02 0 k
(10)Tj
0 g
(].)Tj
2.0749 0 Td
(There-)Tj
-33.9758 -1.3039 Td
(fore,)Tj
2.0352 0 Td
(a)Tj
0.652 0 Td
(retrospective)Tj
5.3631 0 Td
(study)Tj
2.3867 0 Td
(with)Tj
1.9956 0 Td
(26)Tj
1.1736 0 Td
(glaucoma)Tj
4.0762 0 Td
(patients)Tj
3.3675 0 Td
(undergoing)Tj
4.8756 0 Td
(trabeculectomy)Tj
6.3779 0 Td
([)Tj
0.83 0.64 0.02 0 k
(11)Tj
0 g
(])Tj
1.8481 0 Td
(has)Tj
-34.1515 -1.2982 Td
(been)Tj
2.1203 0 Td
(conducted.)Tj
-0.9241 -1.2983 Td
(The)Tj
1.7858 0 Td
(currently)Tj
3.8834 0 Td
(used)Tj
2.0636 0 Td
(preoperative)Tj
5.2271 0 Td
(preparation)Tj
4.9096 0 Td
(in)Tj
1.0374 0 Td
(Mainz)Tj
2.7723 0 Td
(and)Tj
1.7291 0 Td
(other)Tj
2.3471 0 Td
(centres)Tj
3.0727 0 Td
([)Tj
0.83 0.64 0.02 0 k
(12)Tj
0 g
(])Tj
1.8482 0 Td
(has)Tj
1.5477 0 Td
(several)Tj
-33.4202 -1.3039 Td
(potential)Tj
3.7587 0 Td
(disadvantages)Tj
5.7543 0 Td
([)Tj
0.83 0.64 0.02 0 k
(13)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(15)Tj
0 g
(])Tj
3.3221 0 Td
(We)Tj
1.6101 0 Td
(therefore)Tj
3.8551 0 Td
(sought)Tj
2.9027 0 Td
(an)Tj
1.2075 0 Td
(alternative)Tj
4.4164 0 Td
(preoperative)Tj
5.2327 0 Td
(treatment)Tj
-32.0596 -1.2983 Td
(that)Tj
1.7744 0 Td
(would)Tj
2.7156 0 Td
(be)Tj
1.1509 0 Td
(better)Tj
2.5398 0 Td
(tolerated)Tj
3.753 0 Td
(by)Tj
1.1792 0 Td
(patients)Tj
3.3676 0 Td
(in)Tj
1.0374 0 Td
(terms)Tj
2.4945 0 Td
(of)Tj
1.0148 0 Td
(safety)Tj
2.4775 0 Td
(and)Tj
1.7291 0 Td
(quality)Tj
2.9594 0 Td
(of)Tj
1.0148 0 Td
(life,)Tj
1.6667 0 Td
(that)Tj
1.7802 0 Td
(would)Tj
-32.6549 -1.2983 Td
(require)Tj
3.1124 0 Td
(less)Tj
1.61 0 Td
(visits)Tj
2.2281 0 Td
(to)Tj
1.0261 0 Td
(the)Tj
1.4683 0 Td
(ophthalmologist)Tj
6.7521 0 Td
(and)Tj
1.7291 0 Td
(general)Tj
3.1295 0 Td
(practitioner)Tj
4.9492 0 Td
(and)Tj
1.7291 0 Td
(would)Tj
2.7156 0 Td
(therefore)Tj
3.8551 0 Td
(be)Tj
-34.3046 -1.3039 Td
(cheaper,)Tj
3.5659 0 Td
(and)Tj
1.7291 0 Td
(is)Tj
0.8504 0 Td
(that)Tj
1.7745 0 Td
(would)Tj
2.7156 0 Td
(be)Tj
1.1508 0 Td
(equally)Tj
3.0558 0 Td
(effective)Tj
3.5092 0 Td
(in)Tj
1.0375 0 Td
(reducing)Tj
3.7757 0 Td
(IOP)Tj
1.8652 0 Td
(three)Tj
2.2677 0 Td
(and)Tj
1.7291 0 Td
(six)Tj
1.3096 0 Td
(months)Tj
3.2825 0 Td
(after)Tj
2.0353 0 Td
(tra-)Tj
-35.6539 -1.2982 Td
(beculectomy.)Tj
5.4991 0 Td
(No)Tj
1.4627 0 Td
(treatment)Tj
4.1329 0 Td
(guidelines)Tj
4.2803 0 Td
(yet)Tj
1.3946 0 Td
(exist)Tj
2.0353 0 Td
(for)Tj
1.3889 0 Td
(the)Tj
1.4684 0 Td
(pretreatment)Tj
5.4481 0 Td
(prior)Tj
2.2564 0 Td
(to)Tj
1.0205 0 Td
(trabeculectomy.)Tj
-30.3872 -1.2983 Td
(Following)Tj
4.2179 0 Td
(recommendations)Tj
7.5004 0 Td
(by)Tj
1.1792 0 Td
(Klink)Tj
2.4548 0 Td
(et)Tj
0.9411 0 Td
(al)Tj
0.9014 0 Td
([)Tj
0.83 0.64 0.02 0 k
(12)Tj
0 g
(],)Tj
2.0749 0 Td
(we)Tj
1.3267 0 Td
(decided)Tj
3.3391 0 Td
(to)Tj
1.0262 0 Td
(use)Tj
1.5307 0 Td
(preservative-free)Tj
6.8768 0 Td
(-blockers)Tj
-33.3692 -1.3039 Td
(and/)Tj
2.0579 0 Td
(or)Tj
1.0998 0 Td
(carbonic)Tj
3.702 0 Td
(anhydrase)Tj
4.303 0 Td
(inhibitors)Tj
4.1386 0 Td
(as)Tj
1.0148 0 Td
(a)Tj
0.6576 0 Td
(comparator.)Tj
-15.7775 -1.2983 Td
(This)Tj
1.9899 0 Td
(study)Tj
2.3867 0 Td
(investigated)Tj
4.989 0 Td
(the)Tj
1.474 0 Td
(efficacy)Tj
3.2201 0 Td
(and)Tj
1.7291 0 Td
(safety)Tj
2.4832 0 Td
(of)Tj
1.0148 0 Td
(preoperative)Tj
5.227 0 Td
(IOP)Tj
1.8652 0 Td
(reduction)Tj
4.1159 0 Td
(using)Tj
2.3867 0 Td
(two)Tj
1.7122 0 Td
(dif-)Tj
-35.79 -1.2983 Td
(ferent)Tj
2.5738 0 Td
(IOP)Tj
1.8652 0 Td
(lowering)Tj
3.7303 0 Td
(pharmaceutical)Tj
6.3666 0 Td
(interventions)Tj
5.5389 0 Td
(prior)Tj
2.2563 0 Td
(to)Tj
1.0262 0 Td
(trabeculectomy:)Tj
6.599 0 Td
(topical)Tj
2.914 0 Td
(preserva-)Tj
-32.8703 -1.2982 Td
(tive-free)Tj
3.5206 0 Td
(dorzolamide/timolol)Tj
8.4812 0 Td
(eye)Tj
1.525 0 Td
(drops)Tj
2.5058 0 Td
(\(COSOPT-S)Tj
ET
Q
q
1 j
1 J
0 w
7.4999 0 0 6.6659 410.0031 152.4472 cm
BT
/F10 1 Tf
1 TL
-0.0053 Tc
0 0 Td
(1)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 417.4866 148.0251 cm
BT
/F6 1 Tf
1 TL
-0.004 Tc
0 0 Td
(\))Tj
0.5612 0 Td
(\(previously)Tj
4.6885 0 Td
(MSD)Tj
2.3244 0 Td
(SHARP)Tj
3.3278 0 Td
(&)Tj
0.9241 0 Td
(DOHME)Tj
-33.5732 -1.3039 Td
(GmbH,)Tj
3.2541 0 Td
(Germany;)Tj
4.2123 0 Td
(now)Tj
1.9616 0 Td
(Santen)Tj
2.948 0 Td
(OY,)Tj
1.8255 0 Td
(Finland\))Tj
3.6566 0 Td
(compared)Tj
4.2462 0 Td
(to)Tj
1.0261 0 Td
(oral)Tj
1.7745 0 Td
(acetazolamide)Tj
5.8734 0 Td
(plus)Tj
1.8708 0 Td
(topical)Tj
-32.6491 -1.2982 Td
(dexamethasone.)Tj
6.6387 0 Td
(This)Tj
1.9842 0 Td
(trial)Tj
1.8369 0 Td
(also)Tj
1.7688 0 Td
(sought)Tj
2.9083 0 Td
(to)Tj
1.0261 0 Td
(determine)Tj
4.32 0 Td
(whether)Tj
3.4808 0 Td
(the)Tj
1.4684 0 Td
(preoperative)Tj
5.227 0 Td
(treatment)Tj
4.1386 0 Td
(affects)Tj
-34.7978 -1.2983 Td
(postoperative)Tj
5.6012 0 Td
(outcome)Tj
3.7247 0 Td
(\(IOP)Tj
2.2054 0 Td
(and)Tj
1.7291 0 Td
(scarring\),)Tj
4.0308 0 Td
(the)Tj
1.4684 0 Td
(safety)Tj
2.4774 0 Td
(and)Tj
1.729 0 Td
(tolerability)Tj
4.5411 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.474 0 Td
(two)Tj
1.7065 0 Td
(interventions,)Tj
-31.7024 -1.3039 Td
(whether)Tj
3.4752 0 Td
(patients)Tj
3.3676 0 Td
(prefer)Tj
2.6135 0 Td
(one)Tj
1.7008 0 Td
(or)Tj
1.0998 0 Td
(the)Tj
1.4684 0 Td
(other)Tj
2.347 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(tested)Tj
2.5568 0 Td
(therapies)Tj
3.8436 0 Td
(and)Tj
1.7292 0 Td
(health-related)Tj
5.7486 0 Td
(economic)Tj
-32.4337 -1.2983 Td
(aspects.)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 345.2031 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(Preopera)Tj
4.0394 0 Td
(tive)Tj
1.7504 0 Td
(treatment)Tj
4.3795 0 Td
(before)Tj
3.0048 0 Td
(trabecule)Tj
4.0323 0 Td
(ctomy)Tj
2.8559 0 Td
(and)Tj
1.8567 0 Td
(clinical)Tj
3.1465 0 Td
(outcome)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.4748 0 Td
(DOI:10.137)Tj
5.0387 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.0171)Tj
3.5434 0 Td
(636)Tj
2.6362 0 Td
(February)Tj
4.1599 0 Td
(15,)Tj
1.5874 0 Td
(2017)Tj
37.3538 0 Td
(2)Tj
0.7654 0 Td
(/)Tj
0.496 0 Td
(14)Tj
/F8 1 Tf
-0.025 Tc
-66.402 84.0904 Td
(provided)Tj
3.4582 0 Td
(support)Tj
3.0969 0 Td
(in)Tj
0.8859 0 Td
(the)Tj
1.3677 0 Td
(form)Tj
2.0126 0 Td
(of)Tj
0.9496 0 Td
(salaries)Tj
3.0189 0 Td
(for)Tj
1.2544 0 Td
(author)Tj
-16.0442 -1.3748 Td
(AK,)Tj
1.4952 0 Td
(but)Tj
1.4245 0 Td
(did)Tj
1.3606 0 Td
(not)Tj
1.4173 0 Td
(have)Tj
1.956 0 Td
(any)Tj
1.5378 0 Td
(additional)Tj
3.7913 0 Td
(role)Tj
1.6158 0 Td
(in)Tj
0.8858 0 Td
(the)Tj
1.3748 0 Td
(study)Tj
-16.8591 -1.3749 Td
(design,)Tj
2.8984 0 Td
(data)Tj
1.7929 0 Td
(collection)Tj
3.7418 0 Td
(and)Tj
1.5874 0 Td
(analysis,)Tj
3.4087 0 Td
(decision)Tj
3.2953 0 Td
(to)Tj
-16.7245 -1.3748 Td
(publish,)Tj
3.1464 0 Td
(or)Tj
0.9993 0 Td
(preparation)Tj
4.4433 0 Td
(of)Tj
0.9496 0 Td
(the)Tj
1.3677 0 Td
(manuscript.)Tj
/F7 1 Tf
-10.9063 -2.126 Td
(Competing)Tj
4.3795 0 Td
(interests)Tj
3.3307 0 Td
(:)Tj
/F8 1 Tf
0.4819 0 Td
(The)Tj
1.5875 0 Td
(authors)Tj
3.0401 0 Td
(declare)Tj
2.8843 0 Td
(that)Tj
1.6229 0 Td
(they)Tj
-17.3269 -1.3748 Td
(received)Tj
3.3023 0 Td
(a)Tj
0.6378 0 Td
(research)Tj
3.4158 0 Td
(grant)Tj
2.1544 0 Td
(by)Tj
1.1126 0 Td
(MSD)Tj
2.0905 0 Td
(SHARP)Tj
2.9694 0 Td
(&)Tj
-15.6828 -1.3748 Td
(DOHME)Tj
3.2102 0 Td
(GmbH,)Tj
2.8489 0 Td
(Germany)Tj
3.6071 0 Td
(and)Tj
1.5874 0 Td
(Santen)Tj
-11.2536 -1.3748 Td
(Pharmaceu)Tj
4.2165 0 Td
(tical)Tj
1.7079 0 Td
(Co.,)Tj
1.6654 0 Td
(Ltd.,)Tj
1.8709 0 Td
(Japan.)Tj
2.6575 0 Td
(The)Tj
1.5874 0 Td
(author)Tj
2.622 0 Td
(AK)Tj
1.2756 0 Td
(is)Tj
-17.6032 -1.3748 Td
(also)Tj
1.7291 0 Td
(affiliated)Tj
3.3024 0 Td
(with)Tj
1.7787 0 Td
(Augena)Tj
0 Tc
2.4308 0 Td
()Tj
-0.025 Tc
0.3614 0 Td
(rzte)Tj
1.5661 0 Td
(im)Tj
1.1623 0 Td
(Basteicente)Tj
4.2307 0 Td
(r,)Tj
0.7512 0 Td
(a)Tj
-17.3127 -1.3748 Td
(commercial)Tj
4.5779 0 Td
(company.)Tj
3.8835 0 Td
(There)Tj
2.3174 0 Td
(are)Tj
1.3748 0 Td
(no)Tj
1.1622 0 Td
(patents,)Tj
-13.3158 -1.3749 Td
(products)Tj
3.522 0 Td
(in)Tj
0.8859 0 Td
(developm)Tj
3.6283 0 Td
(ent)Tj
1.3678 0 Td
(or)Tj
1.0063 0 Td
(markete)Tj
2.9976 0 Td
(d)Tj
0.6945 0 Td
(products)Tj
3.5221 0 Td
(to)Tj
-17.6245 -1.3748 Td
(declare.)Tj
3.1039 0 Td
(This)Tj
1.7788 0 Td
(does)Tj
2.0126 0 Td
(not)Tj
1.4244 0 Td
(alter)Tj
1.8142 0 Td
(our)Tj
1.474 0 Td
(adherence)Tj
4.0536 0 Td
(to)Tj
0.9496 0 Td
(PLOS)Tj
-16.6111 -1.3748 Td
(ONE)Tj
1.8708 0 Td
(policies)Tj
3.0048 0 Td
(on)Tj
1.1693 0 Td
(sharing)Tj
2.9835 0 Td
(data)Tj
1.7929 0 Td
(and)Tj
ET
endstream
endobj
29 0 obj
<>stream
endstream
endobj
30 0 obj
<>stream
endstream
endobj
31 0 obj
<>stream
endstream
endobj
32 0 obj
<>stream
endstream
endobj
33 0 obj
<>stream
endstream
endobj
34 0 obj
<>stream
endstream
endobj
35 0 obj
<>stream
endstream
endobj
36 0 obj
<>stream
endstream
endobj
37 0 obj
<>stream
endstream
endobj
38 0 obj
<>stream
endstream
endobj
39 0 obj
<>stream
endstream
endobj
40 0 obj
<>stream
endstream
endobj
41 0 obj
<>stream
BT
12.4087 66.8414 Td
(materials.)Tj
ET
Q
endstream
endobj
42 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 12 0 R/Annots 45 0 R/Contents 46 0 R/TrimBox[0 0 612 792]>>
endobj
44 0 obj
<>stream
JFIF C
$, !$4.763.22:ASF:=N>22HbINVX]^]8EfmeZlS[]Y C**Y;2;YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY <"
} !1AQa"q2#BR$3br
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz
w !1AQaq"2B #3Rbr
$4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ? (
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
((kZ:65,0: ̦@\k׳"Fѱ~byPWנ|x/@6S4U|?4UtP? _ #I Q _ #I WAE s |?4U|?4UtP? _ #I Q _ #I WAE s |?4U|?4UtP? _ #I Q _ #I WAE s |?4U|?4UtP? _ #I Q _ #I WAE s |?4U|?4UtP? _ #I Q _ #I WAE s |?4U|?4UtP? _ #I Q _ #I WAE s |?4U|?4UtP? _ #I Q _ #I WAE s |?4U|?4UtP? _ #I Q _ #I WAE s |?4U|?4UtP? _ #I Q _ #I WAE s |?4U|?4UtP? f1GQ.VKQ